These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
440 related articles for article (PubMed ID: 33878340)
1. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340 [TBL] [Abstract][Full Text] [Related]
2. Construction of a reference material panel for detecting Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175 [TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer. Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341 [TBL] [Abstract][Full Text] [Related]
4. Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing. Chen KZ; Lou F; Yang F; Zhang JB; Ye H; Chen W; Guan T; Zhao MY; Su XX; Shi R; Jones L; Huang XF; Chen SY; Wang J Sci Rep; 2016 Aug; 6():31985. PubMed ID: 27555497 [TBL] [Abstract][Full Text] [Related]
5. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer. Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012 [TBL] [Abstract][Full Text] [Related]
6. Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer. Chow YP; Zainul Abidin N; Kow KS; Tho LM; Wong CL PLoS One; 2022; 17(10):e0276161. PubMed ID: 36256645 [TBL] [Abstract][Full Text] [Related]
7. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer. Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403 [TBL] [Abstract][Full Text] [Related]
8. Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients. Gristina V; Russo TDB; Barraco N; Gottardo A; Pepe F; Russo G; Fulfaro F; Incorvaia L; Badalamenti G; Troncone G; Malapelle U; Russo A; Bazan V; Galvano A Sci Rep; 2024 Sep; 14(1):22141. PubMed ID: 39333636 [TBL] [Abstract][Full Text] [Related]
9. Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer. Wang W; Huang Y; Kong J; Lu L; Liao Q; Zhu J; Wang T; Yan L; Dai M; Chen Z; You J Clin Transl Oncol; 2024 Aug; 26(8):1976-1987. PubMed ID: 38777950 [TBL] [Abstract][Full Text] [Related]
10. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525 [TBL] [Abstract][Full Text] [Related]
11. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer. van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317 [TBL] [Abstract][Full Text] [Related]
12. Revolutionizing Non-Small Cell Lung Cancer Diagnosis: Ultra-High-Sensitive ctDNA Analysis for Detecting Hotspot Mutations with Long-term Stored Plasma. Lee JY; Jeon S; Jun HR; Sung CO; Jang SJ; Choi CM; Chun SM Cancer Res Treat; 2024 Apr; 56(2):484-501. PubMed ID: 37871897 [TBL] [Abstract][Full Text] [Related]
13. Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis. Fan G; Zhang K; Ding J; Li J Oncotarget; 2017 May; 8(20):33922-33932. PubMed ID: 28430611 [TBL] [Abstract][Full Text] [Related]
14. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases. Mack PC; Banks KC; Espenschied CR; Burich RA; Zill OA; Lee CE; Riess JW; Mortimer SA; Talasaz A; Lanman RB; Gandara DR Cancer; 2020 Jul; 126(14):3219-3228. PubMed ID: 32365229 [TBL] [Abstract][Full Text] [Related]
15. Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer. Lee Y; Park S; Kim WS; Lee JC; Jang SJ; Choi J; Choi CM Thorac Cancer; 2018 Sep; 9(9):1104-1110. PubMed ID: 29989342 [TBL] [Abstract][Full Text] [Related]
16. Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS Ernst SM; van Marion R; Atmodimedjo PN; de Jonge E; Mathijssen RHJ; Paats MS; de Bruijn P; Koolen SL; von der Thüsen JH; Aerts JGJV; van Schaik RHN; Dubbink HJ; Dingemans AC J Thorac Oncol; 2024 Jul; 19(7):995-1006. PubMed ID: 38615940 [TBL] [Abstract][Full Text] [Related]
17. Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with Ortiz-Cuaran S; Mezquita L; Swalduz A; Aldea M; Mazieres J; Leonce C; Jovelet C; Pradines A; Avrillon V; Chumbi Flores WR; Lacroix L; Loriot Y; Westeel V; Ngo-Camus M; Tissot C; Raynaud C; Gervais R; Brain E; Monnet I; Giroux Leprieur E; Caramella C; Mahier-Aït Oukhatar C; Hoog-Labouret N; de Kievit F; Howarth K; Morris C; Green E; Friboulet L; Chabaud S; Guichou JF; Perol M; Besse B; Blay JY; Saintigny P; Planchard D Clin Cancer Res; 2020 Dec; 26(23):6242-6253. PubMed ID: 32859654 [TBL] [Abstract][Full Text] [Related]
18. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA. Sim WC; Loh CH; Toh GL; Lim CW; Chopra A; Chang AYC; Goh LL Lung Cancer; 2018 Oct; 124():154-159. PubMed ID: 30268455 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations. Ogasawara A; Hihara T; Shintani D; Yabuno A; Ikeda Y; Tai K; Fujiwara K; Watanabe K; Hasegawa K Cancer Res Treat; 2020 Oct; 52(4):1219-1228. PubMed ID: 32599986 [TBL] [Abstract][Full Text] [Related]
20. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF. Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]